Why the study?
Does anti-CD18 antibody reduce myocardial infarct size and neutrophil accumulation in a canine model of ischemia and reperfusion?
Population
Dogs subjected to 90 minutes of ischemia and 3 hours of reperfusion (n=16)
Comparison
Anti-CD18 antibody (F2 fragments of a mouse… vs Control (without anti-CD18 treatment)
Design
Preclinical
Follow-up
3 hours of reperfusion
Authors
Loading...
Anti-CD18 improves microvascular perfusion without limiting infarct size in canine reperfusion; leaves open translation of neutrophil blockade to clinical cardioprotection.
Does anti-CD18 antibody reduce myocardial infarct size and neutrophil accumulation in a canine model of ischemia and reperfusion?
Anti-CD18 antibody reduces neutrophil accumulation and improves postischemic microvascular perfusion but does not limit myocardial infarct size in a canine model of ischemia-reperfusion.
Tanaka et al. (1993) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: